First Quarter of Fiscal 2015 Net sales increased 4% to $87.3 million ; Sales grew 5%, excluding supply agreement Q1 FY15 GAAP $0.02 ; Non-GAAP adjusted net income of $0.16 per share Q1 FY15 EBITDA of $10.8 million , Adjusted EBITDA of $15.3 million Company provides second quarter guidance and

ALBANY, N.Y. , Sept. 25, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2015 first

Event to Benefit St. Jude Children's Research Hospital
Honors WGNA; Features Performance by Big Sky Country

ALBANY, N.Y. , Aug. 7, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today Joseph M. DeVivo , President and Chief Executive Officer, is

Fourth Quarter of Fiscal 2014 Net sales increased 4% to $94.1 million ; Average Daily Sales grew 7%, excluding supply agreement Q4 FY14 GAAP loss of $0.03 per share; Non-GAAP adjusted net income, excluding amortization, of $0.18 per share Q4 FY14 Operating cash flow of $10.1 million Company

ALBANY, N.Y. , July 21, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today receipt of an Innovative Technology Contract for the Company's

ALBANY, N.Y. , July 8, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2014 fourth

ALBANY, N.Y. , June 18, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k)

ALBANY, N.Y. , June 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today it is a winner of Premier Inc.'s first Supplier Horizon Award ,

ALBANY, N.Y. , May 28, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Mark Frost , Executive Vice President and Chief Financial

ALBANY, N.Y. , May 6, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences in

ALBANY, N.Y. , April 29, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Howard W. Donnelly , 52, has been named Chairman of the Board

Net sales increase 8% over prior year to $88.2 million GAAP income per share of $0.14 ; Non-GAAP adjusted net income, excluding amortization, of $0.16 per share Adjusted EBITDA of $14.6 million Company's revenue guidance to $351 million - $355 million for FY14; Adjusted EPS, excluding amortization,

ALBANY, N.Y. , March 25, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results

ALBANY, N.Y. , March 20, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec AG.

ALBANY, N.Y. , March 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded

ALBANY, N.Y. , March 7, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance

Company Acquires Rights to Celerity System, Including Next-Generation Navigation Technology

ALBANY, N.Y. , March 3, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

Net sales of $88.6 million GAAP income per share at break-even; Non-GAAP adjusted net income, excluding amortization, of $0.14 per share Adjusted EBITDA of $12.7 million Operating cash flow of $8.2 million Company raises low end of revenue guidance to $349-$353 million for FY14; reiterates adjusted